Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NETWORK 2OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Breast 1

Conditions

Head and Neck Neoplasms 6Neoplasms 5Carcinoma, Squamous Cell 4Sarcoma, Kaposi 3Hodgkin Disease 3HIV Infections 3Acquired Immunodeficiency Syndrome 3Squamous Cell Carcinoma of Head and Neck 2Lymphoma 2Carcinoma 2Skin Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Laryngeal Diseases 1Hematologic Diseases 1Breast Neoplasms 1

Interventions

pembrolizumab 98Gemcitabine 70Paclitaxel 59Docetaxel 52Carboplatin 49Cisplatin 40Nivolumab 39Capecitabine 35Pemetrexed 33Fluorouracil 32Bevacizumab 32Cetuximab 31130-nm albumin-bound paclitaxel 28Trastuzumab 26Irinotecan 24Albumin-Bound Paclitaxel 24Fulvestrant 22Leucovorin 20Oxaliplatin 18Panitumumab 17abemaciclib 16Ipilimumab 16Cyclophosphamide 15cemiplimab 14atezolizumab 14Letrozole 14palbociclib 12Lapatinib 12Drug Therapy 12Doxorubicin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasm Metastasis × Bleomycin × Clear all
NCT01872923 2014-06-16

Dose Escalating Study for Amphinex-based PCI of Bleomycin.

PCI Biotech AS

Phase 1 Completed
3 enrolled
BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡